SCR-6920

SCR-6920 is a highly potent and selective small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), an enzyme involved in the symmetric dimethylation of arginine residues on histones and other proteins. By inhibiting PRMT5, SCR-6920 reduces levels of symmetric dimethyl arginine (SDMA), leading to anti-tumor effects observed in multiple tumor models. The drug is being developed for the treatment of advanced solid tumors, including non-small cell lung cancer (NSCLC), ovarian cancer (OC), and non-Hodgkin's lymphoma (NHL). It has demonstrated manageable safety and preliminary efficacy signals in early clinical studies. SCR-6920 is administered orally and exhibits fast absorption with a median Tmax less than 1 hour[1][2][4][7].